Summary
14.80 0.02(0.14%)05/16/2024
Caredx Inc (CDNA)
Caredx Inc (CDNA)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 2.75 | 34.62 | 9.59 | 20.23 | 57.77 | 27.41 | -63.45 | 15.58 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 10.46 | |
| Open | 10.20 | |
| High | 10.51 | |
| Low | 9.94 | |
| Volume | 633,993 | |
| Change | 0.28 | |
| Change % | 2.75 | |
| Avg Volume (20 Days) | 621,378 | |
| Volume/Avg Volume (20 Days) Ratio | 1.02 | |
| 52 Week Range | 4.80 - 12.91 | |
| Price vs 52 Week High | -18.98% | |
| Price vs 52 Week Low | 117.92% | |
| Range | 2.55 | |
| Gap Up/Down | -0.14 | |
Fundamentals | ||
| Market Capitalization (Mln) | 756 | |
| EBIDTA | -84,276,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -0.1200 | |
| WallStreet Target Price | 14.40 | |
| Book Value | 4.9480 | |
| Earnings Per Share | -3.5400 | |
| EPS Estimate Current Quarter | -0.2100 | |
| EPS Estimate Next Quarter | -0.1500 | |
| EPS Estimate Current Year | -0.5100 | |
| EPS Estimate Next Year | -0.4100 | |
| Diluted EPS (TTM) | -3.5400 | |
| Revenues | ||
| Profit Marging | -0.6659 | |
| Operating Marging (TTM) | -0.2684 | |
| Return on asset (TTM) | -0.1263 | |
| Return on equity (TTM) | -0.5418 | |
| Revenue TTM | 275,111,008 | |
| Revenue per share TTM | 5.1640 | |
| Quarterly Revenue Growth (YOY) | -0.0670 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 209,581,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.6861 | |
| Revenue Enterprise Value | 0.8541 | |
| EBITDA Enterprise Value | -2.8196 | |
| Shares | ||
| Shares Outstanding | 52,008,100 | |
| Shares Float | 50,740,030 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.13 | |
| Insider (%) | 4.90 | |
| Institutions (%) | 98.02 | |
05/16 16:05 EST - businesswire.com
Landmark Study Shows CareDx's HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced findings from the SHORE (Surveillance HeartCare Outcomes Registry) study, one of the largest heart transplant studies of its kind, published in The Journal of Heart and Lung Transplantation.
Landmark Study Shows CareDx's HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced findings from the SHORE (Surveillance HeartCare Outcomes Registry) study, one of the largest heart transplant studies of its kind, published in The Journal of Heart and Lung Transplantation.
05/09 22:42 EST - seekingalpha.com
CareDx, Inc. (CDNA) Q1 2024 Earnings Call Transcript
CareDx, Inc. (NASDAQ:CDNA ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Greg Chodaczek - Managing Director of Investor Relations John Hanna - President & Chief Executive Officer Abhishek Jain - Chief Financial Officer Alex Johnson - President-Patient & Testing Services Conference Call Participants Bill Bonello - Craig-Hallum Capital Group Prashant Kota - Goldman Sachs Mason Carrico - Stephens Operator Good day, everyone, and welcome to today's CareDx, Inc. First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
CareDx, Inc. (CDNA) Q1 2024 Earnings Call Transcript
CareDx, Inc. (NASDAQ:CDNA ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Greg Chodaczek - Managing Director of Investor Relations John Hanna - President & Chief Executive Officer Abhishek Jain - Chief Financial Officer Alex Johnson - President-Patient & Testing Services Conference Call Participants Bill Bonello - Craig-Hallum Capital Group Prashant Kota - Goldman Sachs Mason Carrico - Stephens Operator Good day, everyone, and welcome to today's CareDx, Inc. First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
05/09 20:01 EST - zacks.com
CareDx (CDNA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
CareDx (CDNA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
05/09 16:05 EST - businesswire.com
CareDx Reports First Quarter 2024 Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights Reported first quarter revenue of $72.0 million. Revenue for Testing Services of $53.8 million, an increase of 15% as compared to the fourth quarter 2023. Grew testing services patients results for the third consecutive quarter to approximately 42,000, an increase of 6% as compared to the fourth quarter 2023. Over 30 oral pre.
CareDx Reports First Quarter 2024 Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights Reported first quarter revenue of $72.0 million. Revenue for Testing Services of $53.8 million, an increase of 15% as compared to the fourth quarter 2023. Grew testing services patients results for the third consecutive quarter to approximately 42,000, an increase of 6% as compared to the fourth quarter 2023. Over 30 oral pre.
05/07 10:20 EST - zacks.com
CareDx (CDNA) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
Beyond analysts' top -and-bottom-line estimates for CareDx (CDNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
CareDx (CDNA) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
Beyond analysts' top -and-bottom-line estimates for CareDx (CDNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
05/03 16:10 EST - businesswire.com
CareDx Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, as an inducement material to entering into employment with CareDx, on April 19, 2024, 17 new employees were awarded restricted stock units (RSUs) for an aggregate of 54,350 shares of co.
CareDx Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, as an inducement material to entering into employment with CareDx, on April 19, 2024, 17 new employees were awarded restricted stock units (RSUs) for an aggregate of 54,350 shares of co.
04/29 16:05 EST - businesswire.com
CareDx to Report First Quarter 2024 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. In.
CareDx to Report First Quarter 2024 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. In.
04/19 16:05 EST - businesswire.com
CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 15, 2024, CareDx granted an option to purchase 700,706 shares of CareDx's common stock (the “Inducement Option”) and 487,804 restricted stock units (the “Inducement RSUs” ) to.
CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 15, 2024, CareDx granted an option to purchase 700,706 shares of CareDx's common stock (the “Inducement Option”) and 487,804 restricted stock units (the “Inducement RSUs” ) to.
04/18 04:51 EST - zacks.com
CareDx (CDNA) Moves 5.5% Higher: Will This Strength Last?
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CareDx (CDNA) Moves 5.5% Higher: Will This Strength Last?
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
04/16 16:02 EST - businesswire.com
CareDx Appoints John W. Hanna as its New President and Chief Executive Officer
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company's Board of Directors, effective April 15, 2024. “John is an outstanding leader with a proven track record of building.
CareDx Appoints John W. Hanna as its New President and Chief Executive Officer
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company's Board of Directors, effective April 15, 2024. “John is an outstanding leader with a proven track record of building.
04/09 07:00 EST - businesswire.com
CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx and study collaborators will be presenting the latest data featuring CareDx's cardiothoracic portfolio at the International Society for Heart and Lung Transplantation (ISHLT) 44th.
CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx and study collaborators will be presenting the latest data featuring CareDx's cardiothoracic portfolio at the International Society for Heart and Lung Transplantation (ISHLT) 44th.
04/01 09:41 EST - zacks.com
How CareDx (CDNA) Stock Stands Out in a Strong Industry
CareDx (CDNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
How CareDx (CDNA) Stock Stands Out in a Strong Industry
CareDx (CDNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
03/11 16:10 EST - businesswire.com
CareDx Appoints Bryan Riggsbee to Its Board of Directors
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that Bryan Riggsbee joins CareDx's Board of Directors, effective March 11, 2024. “We're pleased to welcome Bryan to our Board,” said Michael Goldberg, CareDx Board Chairperson. “His financial.
CareDx Appoints Bryan Riggsbee to Its Board of Directors
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that Bryan Riggsbee joins CareDx's Board of Directors, effective March 11, 2024. “We're pleased to welcome Bryan to our Board,” said Michael Goldberg, CareDx Board Chairperson. “His financial.
02/28 22:22 EST - seekingalpha.com
CareDx, Inc. (CDNA) Q4 2023 Earnings Call Transcript
CareDx, Inc. (CDNA) Q4 2023 Earnings Call Transcript
CareDx, Inc. (CDNA) Q4 2023 Earnings Call Transcript
CareDx, Inc. (CDNA) Q4 2023 Earnings Call Transcript
02/28 20:01 EST - zacks.com
CareDx (CDNA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
CareDx (CDNA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
02/28 16:05 EST - businesswire.com
CareDx Announces Fourth Quarter and Full Year 2023 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter and Full Year 2023 Highlights Reported full year revenue of $280.3 million, exceeding the high end of updated guidance for 2023. Reported full year Testing Services revenue of $209.7 million and delivered approximately 165,700 patient results in 2023. Grew Testing Services patient results for the second quarter in a row to a.
CareDx Announces Fourth Quarter and Full Year 2023 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter and Full Year 2023 Highlights Reported full year revenue of $280.3 million, exceeding the high end of updated guidance for 2023. Reported full year Testing Services revenue of $209.7 million and delivered approximately 165,700 patient results in 2023. Grew Testing Services patient results for the second quarter in a row to a.
02/26 10:21 EST - zacks.com
Unlocking Q4 Potential of CareDx (CDNA): Exploring Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for CareDx (CDNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
Unlocking Q4 Potential of CareDx (CDNA): Exploring Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for CareDx (CDNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
02/21 16:05 EST - businesswire.com
CareDx to Report Fourth Quarter and Full Year 2023 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 28, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30.
CareDx to Report Fourth Quarter and Full Year 2023 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 28, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30.
02/21 07:00 EST - businesswire.com
CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) —The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that it will be showcasing the breadth of its specialized digital solutions and the latest advancements in its cellular therapy and transplant monitoring pipeline at the 2024 Tandem Meetings,.
CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) —The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that it will be showcasing the breadth of its specialized digital solutions and the latest advancements in its cellular therapy and transplant monitoring pipeline at the 2024 Tandem Meetings,.
01/26 21:45 EST - businesswire.com
CareDx Issues Statement in Patent Infringement Case
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the jury verdict in the patent litigation brought by Natera, Inc. (Nasdaq: NTRA). CareDx was found to have not infringed on Natera patent 10,655,180 (the ‘180 patent) and found to have infringed on Natera patent 11,111,544 (the ‘5.
CareDx Issues Statement in Patent Infringement Case
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the jury verdict in the patent litigation brought by Natera, Inc. (Nasdaq: NTRA). CareDx was found to have not infringed on Natera patent 10,655,180 (the ‘180 patent) and found to have infringed on Natera patent 11,111,544 (the ‘5.